Europe Molecular Diagnostics for Infectious Disease Market Forecast to 2030
Europe Molecular Diagnostics for Infectious Disease Market Forecast to 2030 – Regional Analysis – by Type (Point-of-Care Testing and Laboratory Testing), End User [Point-of-Care Testing (Human Testing and Vet Testing) and Laboratory Testing (Human Testing and Vet Testing)], Application [Point-of-Care Testing (Detection of Single Pathogen, Detection of Two or More Pathogens, Evaluation of Emerging Novel Infections, Surveillance and Early Detection of Biothreat Agents and Diseases-Related Biomarker, and Antimicrobial Resistance Profiling) and Laboratory Testing (Patient stratification, Drug Regimen Selection, Toxicity Avoidance, Therapeutic Monitoring, and Detection of Predisposition to Disease)], Disease Type [Point-of-Care Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Mononucleosis, Group A Streptococcus (GAS), and Others) and Laboratory Testing (Sepsis, Prosthetic Joint Infection (PJI), Endocarditis, STDs, Chlamydia, Gastrointestinal Infection, Tuberculosis, H1N1 Virus, and Others)], Infection Type [Point-of-Care Testing (Bacteria, Viral, Fungi, and Others) and Laboratory Testing (Bacteria, Viral, Fungi, and Others)]
$2,840 – $4,440
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases Fuels the Europe Molecular Diagnostics for Infectious Disease Market
Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential for reducing economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally for detecting animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, highly sensitive, and specific, with the ability to detect at a high volume.
Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating swine fever virus, avian influenza virus, classical swine fever virus, and foot-and-mouth disease virus for research purposes. The genesig detection kits of Primerdesign Ltd, UK, supplies lyophilized qPCR assay kits for the diagnosis of 62 bovine, 42 equine, 47 porcine, 60 avian, 40 canine, and 26 feline pathogens for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR.
Thus, molecular diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals can replace the conventional methods such as serological, microscopic, and culture-based techniques.
Europe Molecular Diagnostics for Infectious Disease Market Overview
The European molecular diagnostics for infectious disease market is segmented into Germany, the UK, France, Italy, Spain, Austria, Belgium, the Netherlands, Luxembourg, and the Rest of Europe. The region holds a significant share of the global molecular diagnostics for infectious disease market and is expected to register a notable CAGR during 2022-2030. The market growth in Europe is attributed to an upsurge in life science research and an increase in government investments in testing infectious diseases. According to the data published in an article by the Robert Koch Institute, ~3,900 tuberculosis cases were registered in Germany in 2021. According to this study, ~5% of the test-site visitors in Germany had STD. Moreover, the number of annual visitors for chlamydia and gonorrhea tests had increased from 17% (2017) to 42% (2020). As per the INSTITUT PASTEUR, in France, influenza affects 2-8 million people each year; 10,000-15,000 patients succumb to death due to influenza. It has become a public health issue due to its seasonal outbreaks every year. Other viral infections are also on the rise in the country. As per INSTITUT PASTEUR, 134,000 people are living with chronic hepatitis C virus (HCV) infection, with the addition of ~4,000 new cases annually. According to the WHO, in 2020, ~13,786 deaths were reported due to infectious and parasitic diseases in Italy. Similarly, ~1,303 HIV cases were diagnosed with an incidence of 2.2 per 100,000 residents. As per the Population Reference Bureau, the aging population in Italy was 24% in 2022, which is expected to reach 30% by 2040. Techniques that are used in molecular diagnostic applications are core molecular biology methods such as PCR amplification, sequencing, nucleic acid isolation and quantification, and STR analysis.
Europe Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)
Europe Molecular Diagnostics for Infectious Disease Market Segmentation
The Europe molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.
Based on type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger Europe molecular diagnostics market for infectious disease market share in 2022.
The Europe molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger Europe molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger Europe molecular diagnostics market for infectious disease market share in 2022.
Based on application, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.
Based on disease type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.
Based on infection type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.
Based on country, the Europe molecular diagnostics for infectious disease market is categorized into Germany, the UK, France, Italy, Spain, Austria, Belgium, the Netherlands, Luxembourg, and the Rest of Europe. Germany dominated the Europe molecular diagnostics for infectious disease market in 2022.
Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Molzym GmbH & Co KG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe molecular diagnostics for infectious disease market.
Summary Info
Industry: | |
---|---|
Pricing options: | |
Geographical coverage: | |
Year of Publication: |
According to the Research Team’ research, the Europe molecular diagnostics for infectious disease market was valued at US$ 2,346.42 million in 2022 and is expected to reach US$ 5,948.40 million by 2030, registering a CAGR of 12.3% from 2022 to 2030. Advancements in molecular diagnostics technologies and surging prevalence of infectious disease globally are among the critical factors attributed to the Europe molecular diagnostics for infectious disease market expansion.
Genetic and genomic research has led to the development of molecular diagnostic techniques that focus on nucleic acid detection, which provide new methods for detecting infectious diseases with a fast turnaround time. A molecular diagnostic technique detects multiple pathogens and analyzes drug-resistant genes of pathogens and pathogen homology analysis, making it an increasingly important tool for the early diagnosis of infectious diseases. Molecular diagnostic techniques and platforms are used in all areas of anatomic and clinical pathologies. DNA or RNA sequences associated with disease, including single nucleotide polymorphism, deletions, rearrangements, and insertions, can be detected via molecular diagnostic tests. Conventionally, CT scans, hematological tests, and reverse transcription-PCR (RT-PCR) were used for testing. Due to growing infectious diseases, the need for rapid, precise testing platforms surged to overcome the disadvantages of conventional testing. Computed tomography (CT), a cost-intensive procedure that may not be available in all hospitals, fails to detect viral infections and other diseases in asymptomatic patients. RT-PCR was also time-consuming and could not detect a low viral load during the early stages of infection. Reverse transcription loop-mediated isothermal amplification (RT-LAMP), microarray-based detection, aptamer-based diagnosis, SHERLOCK, SHERLOCKv2, FET Biosensors, cell-based potentiometric diagnosis, and molecular imprinting technology are a few examples of novel molecular diagnostics techniques developed for infectious disease diagnosis. In the last few years, the FDA reports have indicated that molecular testing, antigen-dependent testing, and serological testing have been approved due to the advancements. Collaborative efforts by scientific communities in different countries to manage infectious diseases and reduce the extent of mortality have benefited the overall molecular tools and diagnosis landscape, which will likely create significant opportunities for the molecular diagnostics for infectious diseases market in the future.
On the contrary, limitations associated with molecular testing hampers the growth Europe molecular diagnostics for infectious disease market.
Based on type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held 62.2% share of Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 1,459.00 million. It is projected to garner US$ 3,622.00 million by 2030 to expand at 12.0% CAGR during 2022-2030.
The Europe molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held 94.7% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 840.04 million. It is projected to garner US$ 2,191.08 million by 2030 to expand at 12.7% CAGR during 2022-2030. Additionally, the human testing segment, by laboratory testing, held 94.5% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 1,378.50 million. It is projected to garner US$ 3,404.64 million by 2030 to expand at 12.0% CAGR during 2022-2030.
Based on application, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held 46.6% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 413.64 million. It is projected to garner US$ 1,063.65 million by 2030 to expand at 12.5% CAGR during 2022-2030. Additionally, the drug regimen selection segment, by laboratory testing, held 36.8% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 536.38 million. It is projected to garner US$ 1,326.02 million by 2030 to expand at 12.0% CAGR during 2022-2030.
Based on disease type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held 63.6% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 564.65 million. It is projected to garner US$ 1,506.61 million by 2030 to expand at 13.1% CAGR during 2022-2030. Additionally, the STDs segment, by laboratory testing, held 52.2% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 760.99 million. It is projected to garner US$ 1,928.05 million by 2030 to expand at 12.3% CAGR during 2022-2030.
Based on infection type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held 49.0% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 434.78 million. It is projected to garner US$ 1,119.95 million by 2030 to expand at 12.6% CAGR during 2022-2030. Additionally, the bacteria segment, by laboratory testing, held 48.7% share of the Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 710.52 million. It is projected to garner US$ 1,733.35 million by 2030 to expand at 11.8% CAGR during 2022-2030.
Based on country, the Europe molecular diagnostics for infectious disease market is categorized into the UK, Germany, France, Italy, Spain, Austria, Belgium, Luxembourg, the Netherlands, and the Rest of Europe. Germany held 29.3% share of Europe molecular diagnostics for infectious disease market in 2022, amassing US$ 687.27 million. It is projected to garner US$ 1,699.46 million by 2030 to expand at 12.0% CAGR during 2022-2030.
Key players operating in the Europe molecular diagnostics for infectious disease market are Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Molzym GmbH & Co KG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc, among others.
In Dec 2021, Roche launched the first infectious disease tests and cobas omni Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The launch of the cobas omni Utility Channel enables laboratory professionals the flexibility of running CE-IVD assays, as well as designing their own laboratory developed tests (LDTs). This new offering expands access to critical and robust diagnostic tools that enables healthcare providers to deliver high quality care to patients worldwide, including access to regions with the highest disease burdens.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Europe molecular diagnostics for infectious disease market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the molecular diagnostics for infectious disease market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
4.1 Market Drivers:
4.1.1 Surging Prevalence of Infectious Disease Globally
4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:
5. Molecular Diagnostic for Infectious Diseases Market – Europe Market Analysis
5.1 Europe Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
6. Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Type
6.1 Overview
6.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
6.3.1 Overview
6.3.2 Point-of-Care Testing: Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
6.4.1 Overview
6.4.2 Laboratory Testing: Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
7. Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by End User
7.1 Overview
7.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
7.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
7.2.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
8. Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Application
8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
8.3.1 Overview
8.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
8.4 Laboratory Testing
8.4.1 Overview
8.4.2 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
9. Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Disease Type
9.1 Overview
9.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
9.3.1 Overview
9.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
9.3.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
9.4 Laboratory Testing
9.4.1 Overview
9.4.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
9.4.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
10. Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 – by Infection Type
10.1 Overview
10.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
10.3.1 Overview
10.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
10.4 Laboratory Testing
10.4.1 Overview
10.4.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11. Europe Molecular Diagnostic for Infectious Diseases Market – Country Analysis
11.1 Europe Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
11.1.1 Overview
11.1.2 Europe Molecular Diagnostic for Infectious Diseases Market, by Country
11.1.2.1 UK
11.1.2.1.1 UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.1.2 UK: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.1.3 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.1.4 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.1.5 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.1.6 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.1.7 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.1.7.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.1.8 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.1.8.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.1.9 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.1.10 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.2 Germany
11.1.2.2.1 Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.2.2 Germany: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.2.3 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.2.4 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.2.5 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.2.6 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.2.7 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.2.7.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.2.8 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.2.8.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.2.9 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.2.10 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.3 France
11.1.2.3.1 France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.3.2 France: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.3.3 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.3.4 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.3.5 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.3.6 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.3.7 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.3.7.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.3.8 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.3.8.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.3.9 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.3.10 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.4 Italy
11.1.2.4.1 Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.4.2 Italy: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.4.3 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.4.4 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.4.5 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.4.6 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.4.7 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.4.7.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.4.8 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.4.8.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.4.9 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.4.10 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.5 Spain
11.1.2.5.1 Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.5.2 Spain: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.5.3 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.5.4 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.5.5 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.5.6 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.5.7 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.5.7.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.5.8 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.5.8.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.5.9 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.5.10 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.6 Austria
11.1.2.6.1 Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.6.2 Austria: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.6.3 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.6.4 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.6.5 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.6.6 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.6.7 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.6.7.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.6.8 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.6.8.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.6.9 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.6.10 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.7 Belgium
11.1.2.7.1 Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.7.2 Belgium: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.7.3 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.7.4 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.7.5 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.7.6 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.7.7 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.7.7.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.7.8 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.7.8.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.7.9 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.7.10 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.8 Luxembourg
11.1.2.8.1 Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.8.2 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.8.3 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.8.4 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.8.5 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.8.6 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.8.7 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.8.7.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.8.8 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.8.8.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.8.9 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.8.10 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.9 The Netherlands
11.1.2.9.1 The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.9.2 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.9.3 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.9.4 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.9.5 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.9.6 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.9.7 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.9.7.1 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.9.8 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.9.8.1 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.9.9 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.9.10 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.10 Rest of Europe
11.1.2.10.1 Rest of Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
11.1.2.10.2 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020–2030 (US$ Million)
11.1.2.10.3 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020–2030 (US$ Million)
11.1.2.10.4 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020–2030 (US$ Million)
11.1.2.10.5 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020–2030 (US$ Million)
11.1.2.10.6 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020–2030 (US$ Million)
11.1.2.10.7 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.10.7.1 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020–2030 (US$ Million)
11.1.2.10.8 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020–2030 (US$ Million)
11.1.2.10.8.1 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020–2030 (US$ Million)
11.1.2.10.9 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020–2030 (US$ Million)
11.1.2.10.10 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020–2030 (US$ Million)
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Abbott Laboratories
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 bioMerieux SA
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Danaher Corp
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Hologic Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens Healthineers AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Bruker Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Molzym GmbH & Co KG
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 DiaSorin SpA
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About Us
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Molecular Diagnostic for Infectious Diseases Market Segmentation
Table 2. Europe Molecular Diagnostic for Infectious Diseases Market, for Point of Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 4. Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 6. Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 7. Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 8. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 9. Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 10. Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 11. Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. UK Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 13. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 14. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 15. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 16. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 17. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 18. UK Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 19. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. UK Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 21. UK Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 22. UK Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 23. Germany Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 26. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 31. Germany Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 32. Germany Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 33. Germany Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 34. France Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 35. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 36. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 38. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 39. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. France Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 41. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 42. France Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 43. France Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. France Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 45. Italy Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 46. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 47. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 48. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 49. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 50. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 51. Italy Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 52. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 53. Italy Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 54. Italy Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 55. Italy Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. Spain Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 57. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 58. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 59. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 60. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 61. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 62. Spain Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 63. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 64. Spain Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 65. Spain Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 66. Spain Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 67. Austria Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 68. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 69. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 70. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 71. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 72. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 73. Austria Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 74. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 75. Austria Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 76. Austria Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 77. Austria Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 78. Belgium Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 79. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 80. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 81. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 82. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 83. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 84. Belgium Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 85. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 86. Belgium Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 87. Belgium Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 88. Belgium Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 89. Luxembourg Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 90. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 91. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 92. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 93. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 94. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 95. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 96. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 97. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 98. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 99. Luxembourg Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 100. The Netherlands Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 101. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 102. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 103. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 104. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 105. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 106. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 107. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 108. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 109. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 110. The Netherlands Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 111. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, by Type – Revenue and Forecast to 2030 (US$ Million)
Table 112. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 113. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User – Revenue and Forecast to 2030 (US$ Million)
Table 114. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 115. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application – Revenue and Forecast to 2030 (US$ Million)
Table 116. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 117. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing – Revenue and Forecast to 2030 (US$ Million)
Table 118. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type – Revenue and Forecast to 2030 (US$ Million)
Table 119. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing – Revenue and Forecast to 2030 (US$ Million)
Table 120. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 121. Rest of Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type – Revenue and Forecast to 2030 (US$ Million)
Table 122. Organic Developments Done By Companies
Table 123. Inorganic Developments Done By Companies
Table 124. Glossary of Terms, Molecular Diagnostic for Infectious Diseases Market
LIST OF FIGURES
Figure 1. Europe Molecular Diagnostic for Infectious Diseases Market Segmentation, By Country
Figure 2. Europe Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness
Figure 3. Europe Molecular Diagnostic for Infectious Diseases Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Europe Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 – 2030
Figure 6. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
Figure 7. Point-of-Testing: Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Laboratory Testing: Europe Molecular Diagnostic for Infectious Diseases Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
Figure 10. Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
Figure 11. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
Figure 12. Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
Figure 13. Europe Molecular Diagnostic for Infectious Diseases Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 14. Europe Molecular Diagnostic for Infectious Diseases Market, By Key Countries, 2022 and 2030 (%)
Figure 15. UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 16. Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 17. France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 18. Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 19. Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Rest of Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies – Europe Molecular Diagnostics for Infectious Disease Market
1. Abbott Laboratories
2. bioMerieux SA
3. Bruker Corp
4. Danaher Corp
5. DiaSorin SpA
6. F. Hoffmann-La Roche Ltd
7. Hologic Inc
8. Molzym GmbH & Co KG
9. Siemens Healthineers AG
10. Thermo Fisher Scientific Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.